With network pharmacological analysis, we identified that N-acetyltransferase 2 (NAT2), which is an enzyme that activates or deactivates arylamine and hydrazine of drugs and carcinogens (Hickman et al., 1998), is one of 29 intersecting targets of vitamin D3 against CRC. Here, NAT2 is linked to colorectal carcinoma.